Cancer therapies, including conventional chemotherapeuticssuch as anthracyclines, as well as targeted therapies comprising small-moleculekinase inhibitors, agents targeting human epidermal growth factor receptor 2(HER-2), and specific proteasome inhibitors, have been demonstrated to beassociated with CTRCD [52, 53, 54, 55]. Here, ERBB2 is linked to cancer.